We are a Swiss biopharmaceutical company based at the Biopôle in Epalinges-Lausanne, Switzerland. Our focus is on developing novel anti-tumour somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare diseases, which have unmet medical needs and major market opportunities, including growth hormone producing pituitary brain tumours (acromegaly) and malignant neuroendocrine hormone producing intestinal and pancreatic tumours (NETs) that are resistant or poorly controlled with currently available SSA treatments, octreotide and lanreotide.
13.05.2016
Sompharmaceuticals acquired by Amryt (startupticker.ch)
17.04.2015
Nine hot start-ups, 400 visitors and Joe Jimenez (startupticker.ch)
29.04.2014
SomPharmaceuticals Closes Series A Financing (startupticker.ch)
No milestones
No Jobs
No videos and documents
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
Headquarter:
Epalinges
Foundation Date:
August 2012
Technology:
Sectors: